Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Capital Expenditures: 2011-2024

Historic Capital Expenditures for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $1.7 million.

  • Mimedx Group's Capital Expenditures rose 12.28% to $192,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 45.26%. This contributed to the annual value of $1.7 million for FY2024, which is 15.30% down from last year.
  • As of FY2024, Mimedx Group's Capital Expenditures stood at $1.7 million, which was down 15.30% from $2.0 million recorded in FY2023.
  • Mimedx Group's 5-year Capital Expenditures high stood at $4.2 million for FY2020, and its period low was $1.5 million during FY2022.
  • Over the past 3 years, Mimedx Group's median Capital Expenditures value was $1.7 million (recorded in 2024), while the average stood at $1.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 141.32% in 2020, then plummeted by 52.95% in 2022.
  • Yearly analysis of 5 years shows Mimedx Group's Capital Expenditures stood at $4.2 million in 2020, then declined by 23.89% to $3.2 million in 2021, then tumbled by 52.95% to $1.5 million in 2022, then spiked by 31.24% to $2.0 million in 2023, then decreased by 15.30% to $1.7 million in 2024.